Vensana Capital is a venture capital investment firm that focuses on healthcare with breakthrough innovations in medical technology. The firm was founded in 2018 and is based in Minneapolis, Minnesota, United States.

Vensana Capital

LRVHealth is the “Inside Healthcare” venture capital platform. LRVHealth’s investors include leading provider, payer, and vendor organizations, comprising a network that touches one in three healthcare consumers across the U.S. Together, this network collaborates to identify, invest in, and adopt innovative solutions to the industry’s most pressing needs. Founded in 2000 by an experienced team of healthcare investors, operators, and advisors, the LRVHealth team provides early stage capital, operating experience, and industry insights to build the next generation of great healthcare companies.

LRVHealth

New Leaf Venture Partners is a venture capital firm that invests primarily in healthcare technology. The company typically focuses on later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies.  The New Leaf Ventures (NLV) team has been built over a decade, originating within Sprout Group, the venture capital affiliate of Credit Suisse First Boston. Sprout Group was formed in 1969 and has historically been one of the leading venture capital firms in the country. The team started to invest in healthcare technology in 1993 and since then, has become a leading venture investor in that sector. In 2005, the entire healthcare technology team of Sprout spun out into NLV.

New Leaf Venture Partners

The American College of Cardiology, a 49000-member nonprofit medical society.

American College of Cardiology

At DigiTx Partners,we believe that the pace of change in healthcare will only accelerate in the coming years.  We believe that there are many smart people with great insights and drive who are developing innovative technologies and solutions.  We look forward to supporting innovative companies that will make a difference in our healthcare ecosystem, from companies that will change how patients navigate the healthcare system, that will integrate the disparate elements that comprise both diagnosis and treatment, that will speed the development of more effective drugs and that will enhance and enable efficient and accurate physician-patient interaction.  DigiTx Partners looks forward to investing in those digital health companies that strive to keep all of us in better health.

DigiTx Partners

Cigna Ventures is the arm venture of Cigna, that accelerate growth of start ups in health care industry. The company's mission is to accelerate Cigna’s ability to improve the health, well-being and sense of security of the people we serve by partnering with and investing in innovative companies, and delivering differentiated value in the marketplace. It focuses on harnessing transformative ideas in insights and analytics; digital health and retail; and care delivery and management.

Cigna Ventures

T. Rowe Price is an investment management firm dedicated to funding technology startups. The firm serves individuals, financial intermediaries, and institutions and offers a full range of investment strategies across a broad spectrum: debt, equities, and private equities.

T. Rowe Price

Fidelity is a privately owned investment management firm that serves a wide range of clients. It offers services including IRAs, rollovers, annuities, discount brokerage, retirement planning, estate planning, wealth management, securities execution and clearance, and life insurance. They serve individual investors, businesses, financial advisors, and institutions. The firm manages equity, fixed-income, and balanced mutual funds and invests in public equity and fixed-income markets. It also conducts in-house research to inform its investment decisions.

Fidelity

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.  Their mission is to discover new ways to improve and extend people's lives.  They apply their expertise in science and innovation to society’s biggest health challenges. Responsibility is a core part of their business strategy.

Novartis

Breyer Capital is a premier global venture capital and private equity investor focused on catalyzing high-impact entrepreneurs in the United States and China. Founded by Jim Breyer in 2006, Breyer Capital makes long-term, idea-driven strategic investments in its chosen core areas: social media, entertainment/media, digital health, and financial technologies.  Breyer Capital actively partners with a diverse set of companies including early-stage startups building breakthrough technologies, fast growing companies, and established worldwide leading corporations. Its team enjoys helping to frame strategic investments anchored by the passion of founders and owner/operator teams, the insights of its network of world-class investors, and a conviction that artificial intelligence, machine learning, and virtual reality will transform technology and investment opportunities globally.

Breyer Capital

Sands Capital is an active, long-term investor in innovative growth businesses. The approach combines rigorous fundamental analysis with inspired thinking to seek out businesses that are creating the future. They operate through two affiliates: Sands Capital Management, which focuses on investing in companies in the public market, and Sands Capital Ventures, which focuses on investing in companies in the private market. By enabling clients to participate in the growth of these businesses, its mission is to add value and enhance their wealth with prudence over time.

Sands Capital Ventures

Presight Capital is a venture capital firm investing in the most ambitious founders across sectors, stages, and geographies.  Presight takes a global approach to early-stage investment opportunities in software, frontier technologies & biotech, backed by Apeiron, the family office of Christian Angermayer, and a group of world-class investors: Moore Capital, Point72, Mike Novogratz (former CIO of Fortress Investment Group), Martin Chavez (former CFO of Goldman Sachs), Alan Howard (Brevan Howard), Brent Hoberman (Founders Forum), and many successful entrepreneurs and investors who contribute their respective network and experience.

Presight Capital

South Korean investment firm, headquartered in Seoul.

Mirae Asset Capital

New Leaf Ventures provides strategic, structured financing opportunities to undercapitalized ventures. The company is building a scalable business concept transforming cannabis sector opportunities through the application of professional management and targeted investment to achieve sustainable growth and revenues. New Leaf Ventures intends to rapidly spur growth at New Leaf USA through the rapid execution of its strategic plan as a demonstration to potential future brand partners the importance and inherent power of the House of Brands (“HOB”) business model. HOB offers tangible benefits for adoption and participation in the NLV multi-state operational concept.

New Leaf Ventures

The Catalytic Impact Foundation accelerates breakthroughs — championing extraordinary innovations, catalytic ideas, and, most importantly, visionary leaders. The Foundation aims to solve complex problems and accelerate innovations, alleviate human suffering, address inequities, and improve the quality of human life through disruptive and scalable projects in the life sciences, education, inclusive entrepreneurship and global sustainability. The Foundation is a registered 501(c)(3) charitable organization incorporated in New York State.

THE CATALYTIC IMPACT FOUNDATION (CIF)

Piper Heartland Healthcare Capital is a buyout fund managed by Piper Sandler. The fund targets to invest in healthcare sector.

Piper Heartland Healthcare Capital

Cleerly

Cleerly is a healthcare company whose mission is to create digital care pathways to prevent heart attacks. The company develops a new standard for coronary artery disease by integrating quality clinical science with the latest-generation AI, in order to offer actionable clinical insights to every stakeholder in the heart care pathway. Through these data-driven solutions, the company aims to provide a comprehensive solution for cardiovascular disease evaluation that offers value to the healthcare system and improves heart health for patients at risk of heart attacks.

Cleerly is a digital healthcare company that has developed an AI-enabled platform to help physicians precisely identify, define, and treat heart disease at its earliest stages when it is most treatable. The company's platform leverages non-invasive coronary computed tomography angiography (CCTA) imaging and AI-powered, FDA-cleared solutions to perform comprehensive coronary artery phenotyping. This technology is based on millions of annotated lab images used to build over two dozen proprietary algorithms capable of quantifying and characterizing the presence, extent, severity, and type of coronary artery disease (CAD) and other cardiovascular disorders.

Cleerly Wins 2023 Artificial Intelligence Breakthrough Award

Cleerly adds tools to improve cardiovascular imaging workflows

AI Breakthrough Award Presented to Cleerly CCTA Digital Care Platform

Results of CERTAIN Study Demonstrate Prominent Effects of Cleerly Products on Changing Clinical Management for Patients Suspected of Coronary Artery Disease

Up Cleerly Sees Path Using AI to Prevent Cardiovascular Disease

Personalized Analysis and Treatment of Heart Disease

Cleerly touts new data for AI cardiovascular software

11 AI Health Care Companies Revolutionizing Medicine

How AI is detecting heart attack risk and aiming to outsmart America’s No. 1 killer

Cleerly Takes Center Stage as Best Use of AI in Health Tech Winner at the Fifth Annual Digital Health Hub Foundation Awards

Automation in clinical diagnostics to improve speed and accuracy in patient diagnosis and treatment.

Clinical Decision Support Systems

Cleerly Secures CPT Category I Code for AI-QCT Advanced Plaque Analyses

Cleerly is a digital healthcare company that has developed an AI-enabled platform to help physicians precisely identify, define, and treat heart disease at its earliest stages when it is most treatable. The company's platform leverages non-invasive coronary computed tomography angiography (CCTA) imaging and AI-powered, FDA-cleared solutions to perform comprehensive coronary artery phenotyping. This technology is based on millions of annotated lab images used to build over two dozen proprietary algorithms capable of quantifying and characterizing the presence, extent, severity, and type of coronary artery disease (CAD) and other cardiovascular disorders.
Cleerly's advanced machine learning and AI algorithms enable providers to perform comprehensive assessments of a patient's CCTA, studying each artery and branch to show the patient's risk of CAD in just seven minutes. The diagnostic tools and reporting solutions are tailored to all stakeholders in the heart care pathway, including patients, and the personalized reporting allows providers to deliver precision treatment plans.
In July 2022, Cleerly secured a USD 223 million Series C funding round, bringing its total funding raised to USD 279 million. The company has received two FDA clearances for its products in 2019 and 2020. Cleerly announced positive data from the CERTAIN Study in February 2024, demonstrating the independent and strong incremental impact of its products in changing clinical decision-making and patient management in over 57% of cases compared to conventional CCTA interpretation.

<div>
 
 Clover Health is a healthcare company focused on serving Medicare Advantage members. The company leverages its proprietary software platform, the Clover Assistant, to aggregate and analyze patient data from across the healthcare ecosystem. This data-driven approach aims to support clinical decision-making and improve health outcomes for seniors.
 
 
 
 
 Clover Health operates in two segments: Insurance and Non-Insurance. Through its Insurance segment, the company provides PPO and HMO plans to Medicare Advantage members across several states. As of March 2022, Clover Health had approximately 257,000 lives under its management, a significant increase from around 66,000 lives in the first quarter of 2021.
 
 
 
 
 The Clover Assistant is a key component of Clover Health's strategy. This software platform is designed to provide physicians with relevant patient information to facilitate coordinated care. The company reported that in 2021, its Insurance members whose primary care providers (PCPs) utilized the Clover Assistant had a significantly lower medical care ratio (MCR) compared to members whose PCPs did not use the platform.
 
 
 
 
 In its Non-Insurance segment, Clover Health participates in the Centers for Medicare &amp; Medicaid Services' (CMS) Direct Contracting model, which will transition to the ACO Reach model in 2023. This segment involves aligning with Original Medicare beneficiaries through provider attribution or voluntary alignment.
 
 
 
 
 For the full year 2022, Clover Health expected total revenues to range from USD 3.0 billion to USD 3.4 billion, including projected Insurance revenue of USD 1.0 billion to USD 1.1 billion and Non-Insurance revenue of USD 2.0 billion to USD 2.3 billion. The company also anticipated an improvement in its Insurance MCR, falling within the range of 95% to 99%, driven by operational efficiencies, increased risk scores, and lower Covid-19 costs.
 
 
 
</div>

Clover Health

Digital Diagnostics is a healthcare technology company that develops artificial intelligence (AI) systems for disease diagnosis by analyzing medical images. The company's flagship product, LumineticsCore (formerly known as IDx-DR), is an FDA-cleared autonomous AI system designed to detect diabetic retinopathy and diabetic macular edema during a patient encounter without needing a physician to interpret the images. LumineticsCore increases patient access to care by providing diagnostic results at the point-of-care, eliminating the need for an additional appointment for most patients. This enables healthcare providers to close the gap in eye exams for diabetes care by offering a specialty-level diagnostic exam where the patient receives care.
Digital Diagnostics has also developed DermSpot, an AI system for detecting certain types of skin cancer, which is currently for investigational use only. The company aims to create AI diagnostic solutions that improve patient outcomes, increase healthcare productivity, and enhance accessibility and affordability of care. In April 2023, Digital Diagnostics expanded LumineticsCore to Labcorp patient service centers in Alabama.
Key customers and partnerships
In 2022, Digital Diagnostics signed a long-term strategic partnership with Baxter International to help front-line care providers deliver high-quality care and improve outcomes. The company also partnered with ArchWell Health to bring LumineticsCore to ArchWell Health centers across the US.
Additionally, Digital Diagnostics entered into a memorandum of understanding with the Kingdom of Saudi Arabia's Ministry of Investment in 2022 for international expansion.

Digital Diagnostics

Lunit is a leading provider of AI-powered solutions for cancer diagnostics and therapeutics. The company's flagship product, Lunit INSIGHT, is a suite of AI solutions for radiology that has been approved for commercial use in Europe and the UK through the MDR CE and UKCA certifications obtained in November 2022. The suite includes Lunit INSIGHT CXR for chest X-ray analysis and Lunit INSIGHT MMG for mammography analysis. Lunit INSIGHT CXR can detect 10 chest abnormalities, including pulmonary nodules and pneumothorax, with 97-99% accuracy, while Lunit INSIGHT MMG detects breast cancer with 96% accuracy.
After receiving FDA clearance, Lunit's solutions are clinically used in approximately 3,000 hospitals and medical institutions across 40 countries as of March 2024. In April 2024, a study published in European Radiology demonstrated that Lunit INSIGHT MMG could potentially reduce radiologists' workload by nearly 70% and boost cancer detection accuracy by 30.5%, showcasing its ability to enhance operational efficiency and improve patient outcomes.
In May 2024, Lunit completed the acquisition of Volpara Health Technologies, a New Zealand-based company offering software for early cancer detection, for USD 193 million. The acquisition aimed to strengthen Lunit's presence in the US market and leverage Volpara's robust repository of over 100 million medical images to develop innovative solutions for cancer diagnostics.
Key customers and partnerships
Lunit has established strategic partnerships to expand its reach and integrate its AI solutions into healthcare systems worldwide. In March 2024, the company signed supply contracts with Chung Shan Medical University in Taiwan and Gleneagles Hospital in Singapore to provide Lunit INSIGHT CXR and Lunit INSIGHT MMG, respectively. These collaborations aimed to enhance lung and breast cancer detection in the East and Southeast Asian regions.
In November 2023, Lunit partnered with NTT DATA Singapore to introduce Lunit INSIGHT CXR to Singapore's public healthcare system through the AimSG platform, a national medical imaging AI initiative. The solution was piloted at Singapore General Hospital and Changi General Hospital, two major public hospitals, to enhance the efficiency of chest screening and provide innovative medical services with improved accuracy.
Lunit has also collaborated with leading healthcare technology companies, such as GE healthcare, Fujifilm, Philips, and Guardant Health, to deploy its AI products and leverage their distribution networks.

Lunit

Lumeon is a digital health company that provides a cloud-based Care Orchestration platform designed to automate and streamline the care coordination process for healthcare providers. The platform leverages real-time, bi-directional data integration and applies dynamic clinical intelligence to ensure that patients receive the right care at the right time, every time.
Lumeon's Care Orchestration platform acts as a "care traffic control" center, synchronizing disparate data across the care continuum, orchestrating and automating care pathway activities, and delivering relevant information to care teams and patients. By automating routine tasks and workflows, the platform enables care teams to focus on providing direct patient care, working at the top of their licenses.
The platform integrates with electronic health records (EHRs) and other systems, creating a real-time synthetic patient record to inform care decisions. It visualizes care plans, virtualizes monitoring, and automates routine tasks, ultimately reducing manual intervention and associated costs for providers. The platform can be deployed enterprise-wide and applied across various use cases within a healthcare system.
Key features of Lumeon's Care Orchestration platform include real-time bi-directional data integration with EHRs and other systems, automation of care orchestration tasks and workflows, and the ability to present information through multiple modalities, including within EHRs, native interfaces, web portals, and mobile apps.
Lumeon's platform has been deployed by leading healthcare providers in the US and Europe across more than 2,000 care locations, delivering measurable results in as little as 90 days.

Lumeon

Proscia is a software company that develops digital and computational pathology solutions. Its flagship product, Concentriq, is an enterprise pathology platform that serves as a hub for digital pathology data and AI applications. Concentriq bridges the gap between anatomic pathology laboratories and life sciences organizations, enabling real-world pathology data to fuel innovation that enhances patient care.
The platform delivers an open environment to run a range of AI applications, including Proscia's proprietary algorithms and those developed by partners or customers. One such AI solution is DermAI, a dermatopathology module launched in June 2019 to assist laboratories in tasks like case prioritization, automated quality assurance, and enhanced technical component reporting.
In February 2024, Proscia received 510(k) clearance from the FDA for its Concentriq AP-Dx solution for primary diagnosis in clinical settings. This comprehensive diagnostic software streamlines collaboration and helps drive confidence and efficiency gains. As of December 2023, over 10,000 pathologists and scientists, including those at leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies, used Proscia's solutions.
Furthermore, in December 2023, CellNetix Pathology & Laboratories announced a collaboration with Proscia to digitize a portion of its 1 million glass slides per year and adopt AI-powered digital pathology workflows.

Proscia

Software that provides a list of possible diseases based on data collected from patients. Platforms are only used for initial assessments.

Platforms and software that generates alerts based on patient treatment and current status.

Platforms and software that monitor and track treatment plans of patients, identifies possible treatment issues, and suggests alternative treatment options.

Workflow management software that helps clinicians track and follow procedure for operations.

Companies that use GenAI as a core part of their product offering for Clinical Decision Support Systems

Uses digital mediums to generate actionable insights from health data

Clinical Decision Support System providers incorporate GenAI to enhance their systems

In most cases, CDSSs are provided to healthcare providers

Uses IoT to connect databases with medical devices for decision support

Uses AI/ML to output decisions/recommended actions based on databases of medical records

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

ANALYST_QUICK_TAKE

PROMINENT_CATEGORY

<div>
 Viz.ai, a California-based firm that specializes in AI-powered diagnostics and care coordination, has entered into a partnership with Cleerly, a company that diagnoses heart disease. The goal is to improve coordination of cardiovascular care.
 In the arrangement, Cleerly's FDA-approved AI software, used for analysis of coronary computed tomography angiography, will be integrated into Viz.ai's One platform. The collaboration is intended to improve heart disease detection and diagnosis, streamline the workflows of physicians, and enhance patient outcomes through AI-powered diagnostics for cardiovascular health. The combined solution will be accessible to over 1,600 hospitals that utilize Viz.ai's platform.
 
</div> Analyst QuickTake : 
 This integration expands Viz.ai's AI platform, which includes features like ECG AI, echo AI, and chest CT visualization. Additionally, in 2022, the company partnered with Singapore-based software development company <a href="https: 
//sp-edge.com/updates/14273"> Us2.ai </a> to offer echocardiogram analysis within its platform.

Cleerly

Sources

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless